APTN
ADAPTIN BIO, INC.
Biopharma developer (SEC filing verified)·Charlotte, NC, United States·CEO: Dr. Michael J. Roberts Ph.D.
AI OverviewAI overview is shown in English only.
ADAPTIN BIO, INC. (APTN) is a clinical-stage biotechnology company developing APTN-101, an EGFRvIII x CD3 bispecific T cell engager designed to treat glioblastoma and other EGFRvIII-expressing tumors, with its lead candidate accepted under an investigator-led IND for first-in-human studies.
- APTN-101 is a proprietary EGFRvIII x CD3 bispecific T cell engager designed to redirect T cells against tumors expressing a mutated form of EGFR, including glioblastoma, breast, and lung cancer [sec_mda · as of 2026-08-13].
- The FDA accepted the IND for APTN-101 in May 2023 and accepted the amended IND in October 2025 for a multi-dose first-in-human clinical trial in glioblastoma patients [sec · filed 2026-08-28].
- As of June 30, 2026, the company had cash and cash equivalents of $670,488 and an accumulated deficit of $11,643,209 [sec · filed 2026-08-28].
- For the six months ended June 30, 2026, the company recorded a net loss of $2,351,408 [sec · filed 2026-08-28].
- The company's common stock is quoted on the OTCQB Venture Market under the ticker symbol APTN, with 9,244,937 shares outstanding as of August 25, 2026 [sec · filed 2026-08-28].
What works
- APTN-101 has demonstrated the ability to eliminate malignant glioma tumors in aggressive preclinical orthotopic tumor models, supporting its potential as a targeted therapy [sec_mda · as of 2026-08-13].
- The FDA's acceptance of the IND and amended IND for APTN-101 in 2023 and 2025, respectively, indicates regulatory progress toward first-in-human studies [sec · filed 2026-08-28].
- The company's proprietary platform integrates recombinant technology, gene therapy, and cell therapy, positioning it to address brain cancer and other unmet medical conditions [sec_mda · as of 2026-08-28].
- APTN-101 is designed to target a well-characterized, mutated form of EGFR (EGFRvIII) that is expressed on multiple tumor types, broadening its potential applicability [sec_mda · as of 2026-08-13].
What to weigh
- The company has incurred significant operating losses since inception and expects to continue incurring losses for the foreseeable future, with no revenue generated to date [sec_mda · as of 2025-04-15].
- As of June 30, 2026, cash and cash equivalents were only $670,488, which may be insufficient to fund operations for the next twelve months, raising going-concern uncertainties [sec · filed 2026-08-28].
- The company's ability to raise additional capital is a key risk, as it may need to secure funding to continue development of APTN-101 and other candidates [sec · filed 2026-08-28].
- APTN-101 is still in early-stage development, with first-in-human studies only recently accepted under an investigator-led IND, meaning significant clinical and regulatory hurdles remain [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
APTN-101 is a proprietary EGFRvIII x CD3 bispecific T cell engager designed to target EGFRvIII-expressing tumors, including glioblastoma, breast, and lung cancer.
“APTN-101, a proprietary EGFRvIII x CD3 bispecific T cell engager, that is able to eliminate malignant glioma tumors in a variety of aggressive preclinical orthotopic tumor models.”
SEC MD&A · August 13, 2026
The FDA accepted the IND for APTN-101 in May 2023 and the amended IND in October 2025 for a multi-dose first-in-human trial in glioblastoma patients.
“The FDA's acceptance in May 2023 of the IND for APTN-101 and its acceptance in October 2025 of the amended IND for APTN-101 for the multi-dose first-in-human clinical trial in glioblastoma patients support the continued advancement of APTN-101.”
SEC filings · August 28, 2026
The company recorded a net loss of $2,351,408 for the six months ended June 30, 2026.
“For the three and six months ended June 30, 2026, we recorded a net loss of $1,205,312 and $2,351,408, respectively.”
SEC MD&A · August 28, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Cash of $670,488 as of June 30, 2026 may be insufficient to fund operations for the next twelve months [sec · filed 2026-08-28].
- Dependence on APTN-101 success — APTN-101 is the lead candidate; failure in clinical trials would materially harm the company [sec_mda · as of 2026-08-13].
- Need for additional capital — The company expects to incur significant losses and may need to raise additional funds to continue development [sec · filed 2026-08-28].
- Regulatory and clinical hurdles — APTN-101 is in early-stage development; regulatory approval is uncertain and subject to clinical trial outcomes [sec · filed 2026-08-28].
What to watch
- Initiation and progress of the first-in-human clinical trial for APTN-101 in glioblastoma patients, following FDA acceptance of the amended IND [sec · filed 2026-08-28].
- The company's ability to raise additional capital to fund operations and development, given the limited cash position as of June 30, 2026 [sec · filed 2026-08-28].
- Any updates on preclinical development of APTN-101 for additional cancer indications, as the company plans to advance toward additional INDs [sec · filed 2026-08-28].
- Financial results for subsequent quarters, which will indicate whether the company can manage its cash runway effectively [sec · filed 2026-08-28].
Sources: SEC filings · SEC MD&A · Generated September 25, 2026 · How we verify sources →
Run ADAPTIN BIO, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ADAPTIN BIO, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Governance
Frequently asked questions
What is the AI investment thesis for ADAPTIN BIO, INC.?
ADAPTIN BIO, INC. (APTN) is a clinical-stage biotechnology company developing APTN-101, an EGFRvIII x CD3 bispecific T cell engager designed to treat glioblastoma and other EGFRvIII-expressing tumors, with its lead candidate accepted under an investigator-led IND for first-in-human studies.
Who is the CEO of ADAPTIN BIO, INC.?
Dr. Michael J. Roberts Ph.D. is the chief executive officer of ADAPTIN BIO, INC. (APTN).
Where is ADAPTIN BIO, INC. headquartered?
ADAPTIN BIO, INC. (APTN) is headquartered in Charlotte, NC, United States.
923 companies304,840 SEC filings22,637 clinical trials100% citation-verification pass rate (7d)How we verify →
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.